Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial

BACKGROUND: Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to re...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Am J Nephrol
Päätekijät: Ruilope, Luis M., Agarwal, Rajiv, Anker, Stefan D., Bakris, George L., Filippatos, Gerasimos, Nowack, Christina, Kolkhof, Peter, Joseph, Amer, Mentenich, Nicole, Pitt, Bertram
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: S. Karger AG 2019
Aiheet:
Patient-Oriented, Translational Research: Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6889917/
https://ncbi.nlm.nih.gov/pubmed/31665733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000503712
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia